History of Kyowa KirinLearn more about our heritage and
contributions to healthcare

Kyowa Kirin is a pharmaceutical company,
formed from a combination of the depth of
and strong business record of
Kyowa Hakko Kogyo and Kirin Pharma.

Find out the combined histories of Kyowa
Hakko Kogyo and Kirin Pharma, followed by the history
of Kyowa Kirin,
touching upon their
performance in the field of research and
development to date.


Establishment of Kirin Brewery Co., Ltd.

Kirin Brewery Co., Ltd.


Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.

Kyowa Hakko Kogyo Co., Ltd.


Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).

Lapping bus for commerce of Streptomycin


Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C.

Invention of the process of L-glutamic acid production by fermentation (a world first).


Initiation of full-scale involvement in the pharmaceutical business.

Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.


Release of 5-FU, an anticancer drug.


Release of Leunase, an anticancer drug.


The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.


Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).

La Jolla Institute


Release of ESPO®, an erythropoietin (EPO) drug.


Release of GRAN®, G-CSF drug.

Release of Coniel, a remedy for hypertension and agina pectoris.


Establishment of fully human antibody production technology.


Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.


The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP®, a long-acting erythropoietic stimulating drug.

Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary.

Capital alliance between Kyowa Hakko Group and Kirin Group.


Release of REGPARA®, a drug for secondary hyperparathyroidism.

Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd.

Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.


Introduced "Commitment to Life".


Acquired ProStrakan Group plc.


Launch of Poteligeo® in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL).


Launch of NOURIAST® tablets 20 mg in Japan, a novel antiparkinsonian agent.


ProStrakan Completes Acquisition of Archimedes.

Launch of Sustained-Duration G-CSF Product G-LASTA® in Japan.


Rebranding Western Pharmaceutical Subsidiaries to "Kyowa Kirin".

Launch of LUMICEF® for Psoriasis Treatment in Japan.


Crysvita® approved in the US and Europe, sales to start as a treatment for patients with X-linked hypophosphatemia.

Poteligeo® approved in the US and Europe as a treatment for mycosis fungoides (MF) and Sézary syndrome (SS).


Trade name changed to current "Kyowa Kirin Co., Ltd." from Kyowa Hakko Kirin Co., Ltd.

Crysvita® launched in Japan for the treatment of FGF23-related Hypophosphatemic Rickets and Osteomalacia.

Nourianz™ launched in the US for use in Parkinson's disease.

CI logo of Kyowa Kirin


Poteligeo® launched in Europe for the treatment for mycosis fungoides (MF) and Sézary syndrome (SS).

Crysvita® approved in the US for the treatment of tumor-induced osteomalacia (TIO).


New Vision toward 2030 designed to realize the creation and delivery of life-changing value.

Agreement reached with Amgen to jointly develop and commercialize KHK4083, a Kyowa Kirin-discovered anti-OX40 fully human monoclonal antibody.

Declared support for the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD).


Global DE&I Statement adopted with 40% of global leaders to be female by 2030.

An automated injection device "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod" launched in Japan for the long-acting G-CSF preparation, G-Lasta®.

Q-TOWER, the new biopharmaceutical analysis facility completed at Takasaki Plant, Kyowa Kirin's major biopharmaceutical manufacturing site.


PHOZEVEL® approved in Japan for the treatment of Hyperphosphatemia in chronic kidney disease patients.

Kyowa Kirin announced the aquisition of UK company Orchard Therapeutics with strength in hematopoietic stem cell gene therapy.